PatentJun 16, 2026, 07:31 AM
Cognition Therapeutics Receives Patent for Zervimesine, Extends Protection to 2045
AI Summary
Cognition Therapeutics announced it received a Notice of Allowance from the USPTO for a patent covering a polymorphic crystalline form of zervimesine (CT1812), its lead drug candidate. This patent, once issued, will protect the key formulation through 2045, with a potential extension to 2050. The new form offers enhanced stability and will be used in upcoming registrational trials for dementia with Lewy bodies (DLB) psychosis.
Key Highlights
- Cognition Therapeutics received a Notice of Allowance from the USPTO for patent application 19/563,468.
- The patent covers a polymorphic crystalline form of zervimesine (CT1812), the company's lead drug candidate.
- Once issued, the patent will provide protection for this formulation through 2045, with a potential extension to 2050.
- The patent covers composition of matter, a specialized production process, and therapeutic methods for neurodegenerative disorders.
- The new polymorphic form offers a more favorable pharmaceutical profile with greater thermodynamic and chemical stability.
- The company plans to use this new form of zervimesine in registrational trials for DLB psychosis.
Price Impact
More from CGTX